Hannah Clarke

ADV7103 is currently being studied in the phase 2/3 CORAL-1 study, enrolling patients with cystinuria across centers in France and Belgium.

"Indeed, HSD3B1 appears to be the most common monogenic driver of prostate cancer mortality,” says Nima Sharifi, MD.

Astellas expects a decision on EU marketing authorization of enzalutamide in nmHSPC by June 2024.

"We suspect that 340B hospitals potentially have some resources or mechanisms that are helping these vulnerable patients maintain adherence,” says Kassem S. Faraj, MD.

"The ProVee System has the potential to be a first-line interventional therapy for BPH that can be safely and reliably performed in the office setting," says Steven A. Kaplan, MD.

The EdgeFlow UH10 bladder scanner utilizes high-resolution ultrasound imaging to non-invasively measure postvoid residual urine in the bladder.

According to Axonics, commercial sales of the R20 system in Europe are expected to begin in mid-April.

Overall, the phase 1/2 trial is designed to explore the safety, tolerability, pharmacokinetics, and preliminary clinical activity of NUV-1511 in patients with advanced solid tumors.

"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.

Among all patients treated in the study to date, 60% demonstrated a PSA reduction of greater than 35%, and 27% demonstrated a PSA reduction of greater than 80%.

The VISTA-101 study has dosed all patients at dose level 5 of 6 in the KVA12123 monotherapy arm and all patients at the dose level 2 of 4 in the KVA12123-pembrolizumab combination arm.

The study is assessing RECCE 327 across the infusion times of 15, 20, 30, 45, and 60 minutes at the dose level of 3000 mg.

“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.

“This research suggests that proactive and continuous management of metabolic syndrome may serve as an essential strategy in preventing cancer," says Han-Ping Shi, MD, PhD.

"Now, physicians in Canada have a once-daily oral GnRH antagonist treatment option in their armamentarium that helps men with advanced prostate cancer by lowering testosterone levels without leading to testosterone flares,” said Fred Saad, MD, FRCS.

Artus is an artificial urinary sphincter for the treatment of patients with moderate to severe urinary incontinence.

Preliminary data showed that the treatment was well-tolerated, and a maximum tolerated dose had not yet been reached.

In this interview, Joshua Langston, MD, highlights a session on Medicare reimbursement reform from the 7th Annual AUA Urology Advocacy Summit.

The therapy is currently being manufactured in Italy at Curium facilities in Milan.

"We are confident in PT-112's potential as an effective treatment for patients with mCRPC who have progressed on androgen receptor directed therapy, chemotherapy or radioligand therapy and who lack any effective immunotherapy," says Robert Fallon.

Overall, lesions less than 5 mm in size were detected across readers in 14% (7 of 50) of patients.

The approval is based on data from the phase 3 CheckMate-901 trial, which demonstrated improved overall survival and progression-free survival with the nivolumab-combination therapy vs cisplatin/gemcitabine alone.

Data showed that the combination of EV and pembrolizumab extended overall survival and progression-free survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

"We found that PSA levels vary by ethnicity, Black men had higher PSA levels than White men, and Asian men had the lowest PSA levels,” says Elizabeth Down.

The FIT-001 trial is assessing KO-2806 as a monotherapy and in combination with targeted therapies in patients with advanced solid tumors, including ccRCC.

“This significant milestone not only celebrates ArteraAI's success but also paves the way for the integration of AI-enabled solutions into clinical practice, illustrating their potential to enhance personalized patient care," says Andre Esteva.

The CMS payment rate for the tests went into effect on January 1, 2024.

“The test is designed to non-invasively identify the presence of aggressive cancer in men already diagnosed with prostate cancer who are on or are considering starting active surveillance,” says Kirk J. Wojno, MD.

"We looked at people who were in the intermediate-risk zone, and we found that our calculator did do a better job of helping some of those men avoid unnecessary biopsies," says Adam B. Murphy, MD, MBA, MSCI.

The study plans to enroll 144 patients with solid tumors, including RCC, non-small cell lung cancer, colorectal carcinoma (CRC), and other malignancies known to express HHLA2/B7-H7.